Latest Insider Transactions at Igm Biosciences, Inc. (IGMS)
This section provides a real-time view of insider transactions for Igm Biosciences, Inc. (IGMS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IGM Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IGM Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2023
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
738
+1.87%
|
-
|
|
Mar 31
2023
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
492
+0.65%
|
-
|
|
Mar 31
2023
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
1,108
+0.11%
|
-
|
|
Mar 14
2023
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,293
-1.41%
|
$23,274
$18.73 P/Share
|
|
Mar 14
2023
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,768
-6.53%
|
$31,824
$18.73 P/Share
|
|
Mar 14
2023
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,768
-5.79%
|
$31,824
$18.73 P/Share
|
|
Mar 14
2023
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,061
-5.96%
|
$19,098
$18.73 P/Share
|
|
Mar 14
2023
|
George Gauthier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,061
-5.41%
|
$19,098
$18.73 P/Share
|
|
Jan 31
2023
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
533
+1.44%
|
-
|
|
Jan 31
2023
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
533
-100.0%
|
-
|
|
Jan 05
2023
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
33,756
+26.84%
|
$0
$0.93 P/Share
|
|
Dec 30
2022
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
230
+9.66%
|
-
|
|
Dec 30
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
230
+0.01%
|
-
|
|
Dec 30
2022
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
374
+9.03%
|
-
|
|
Dec 30
2022
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
533
+50.0%
|
-
|
|
Dec 30
2022
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
346
+0.9%
|
-
|
|
Dec 30
2022
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
230
+0.31%
|
-
|
|
Dec 19
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,801
-12.3%
|
$76,020
$20.0 P/Share
|
|
Dec 16
2022
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
2,484
-6.31%
|
$47,196
$19.07 P/Share
|
|
Dec 16
2022
|
George Gauthier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,354
-9.51%
|
$82,726
$19.07 P/Share
|
|
Dec 16
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
5,371
-4.31%
|
$102,049
$19.07 P/Share
|
|
Dec 16
2022
|
Fred Schwarzer CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
12,369
-21.06%
|
$235,011
$19.07 P/Share
|
|
Dec 16
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,283
-3.5%
|
$43,377
$19.07 P/Share
|
|
Dec 16
2022
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,430
-7.83%
|
$103,170
$19.07 P/Share
|
|
Dec 14
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+28.21%
|
$0
$0.93 P/Share
|
|
Nov 23
2022
|
Fred Schwarzer CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,258
-1.87%
|
$26,418
$21.68 P/Share
|
|
Nov 23
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
877
-1.3%
|
$18,417
$21.68 P/Share
|
|
Nov 23
2022
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
877
-1.2%
|
$18,417
$21.68 P/Share
|
|
Nov 23
2022
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,258
-2.96%
|
$26,418
$21.68 P/Share
|
|
Nov 23
2022
|
George Gauthier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,258
-2.52%
|
$26,418
$21.68 P/Share
|
|
Nov 23
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
877
-1.12%
|
$18,417
$21.68 P/Share
|
|
Nov 15
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
353
+1.03%
|
$4,236
$12.84 P/Share
|
|
Nov 08
2022
|
M Kathleen Behrens |
BUY
Open market or private purchase
|
Indirect |
60,000
+21.57%
|
$1,020,000
$17.14 P/Share
|
|
Oct 14
2022
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
533
+1.47%
|
-
|
|
Oct 14
2022
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
533
-100.0%
|
-
|
|
Oct 04
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
25,000
-38.77%
|
$550,000
$22.84 P/Share
|
|
Oct 04
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+27.94%
|
$0
$0.93 P/Share
|
|
Oct 03
2022
|
Redmile Group, LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
221,072
+6.21%
|
$4,863,584
$22.49 P/Share
|
|
Oct 03
2022
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
221,072
-6.21%
|
$4,863,584
$22.49 P/Share
|
|
Sep 30
2022
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
230
+10.69%
|
-
|
|
Sep 30
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
230
+0.01%
|
-
|
|
Sep 30
2022
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
230
+0.31%
|
-
|
|
Sep 30
2022
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
346
+0.91%
|
-
|
|
Sep 30
2022
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
533
+50.0%
|
-
|
|
Sep 30
2022
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
374
+9.93%
|
-
|
|
Sep 29
2022
|
Michael D Loberg Director |
BUY
Open market or private purchase
|
Indirect |
5,821
+14.15%
|
$110,599
$19.62 P/Share
|
|
Sep 28
2022
|
Michael D Loberg Director |
BUY
Open market or private purchase
|
Indirect |
6,172
+17.31%
|
$123,440
$20.97 P/Share
|
|
Sep 27
2022
|
Michael D Loberg Director |
BUY
Open market or private purchase
|
Indirect |
507
+2.13%
|
$9,633
$19.99 P/Share
|
|
Sep 08
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-10.58%
|
$190,000
$19.96 P/Share
|
|
Sep 08
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.81%
|
$0
$0.93 P/Share
|